Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.

Our transformative product candidates - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.

Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients. In order to fully exploit the potential of Immatics' product pipeline and technologies we invite others to join us on this exciting mission.

Our Partners


GSK and Immatics enter Strategic Collaboration to develop novel adoptive cell therapies targeting multiple cancers indications, Feb 20, 2020.

Learn more


Immatics and Celgene, a Bristol-Myers Squibb Company, Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies, Aug 28, 2019.

Learn more


Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies, Jul 12, 2018.

Learn more


Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies, Jan 09, 2017.

Learn more


Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies, Aug 26, 2015.

Learn more


MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology, Aug 25, 2015.

Learn more


Immatics and Roche sign cancer vaccine and immunotherapy collaboration, Nov 13, 2013.

Learn more

Contact Us about Partnering Opportunities


Immatics Biotechnologies GmbH
Business Development Group

Machtlfinger Str. 11
81379 München

We use cookies to ensure that we give you the best experience on our website.